SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as investors discuss its volatile price action and potential acquisition of Larvotto Resources, with some expressing concerns about valuation and dilution. Community members are weighing the impact of US-China trade relations and the company's strategic position in antimony production, particularly in light of government contracts and expansion plans. Bullish investors are accumulating shares, anticipating future growth and potential government support for UAMY's role in securing domestic supply chains.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm shares jumped following the unveiling of its new AI200 and AI250 chips aimed at the data center market, positioning the company to compete with Nvidia and AMD. The community is buzzing about the significance of this move into AI hardware, with some analysts skeptical of the long-term impact and revenue potential, while others see it as a potential game-changer. Heavy options activity and unusual trading patterns suggest strong interest and debate around the stock's future direction as it shifts from mobile chips to AI infrastructure.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels ($UUUU) is trending due to significant call option activity, signaling potential insider knowledge of upcoming positive news or government contracts related to rare earth elements. The community is actively discussing large call sweeps and the potential for a short squeeze. The stock is further supported by a recent joint venture in Australia and a broader focus on domestic uranium production amid geopolitical tensions.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as discussions revolve around its potential breakout and the upcoming vote on Elon Musk's compensation package, with some believing approval is crucial for the company's future. Community debates center on Tesla's valuation, profitability, and the impact of Musk's leadership and AI advancements. Traders are actively monitoring key price levels, anticipating volatility and potential shorting opportunities if certain resistance levels hold.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending as traders discuss its potential for a short squeeze, focusing on its low float and high insider ownership. The community is also highlighting the company's recent revenue growth, government contracts, and possible interest in a crypto treasury, while remaining aware of risks associated with China-based stocks.

MaxsMaking, Inc. is a holding company, which engages in the manufacture of customized consumer goods. It offers a range of customizable textile products, including backpacks, thermal bags, canvas bags, aprons, throw pillows, flags, and advertising chair covers. The company was founded by Xiao Zhong Lin and Xue Fen Zhang in January 2007 and is headquartered in Shanghai, China.

MaxsMaking Inc. - Ordinary Shares - Class A

MaxsMaking Inc. Class A Ordinary Shares

MaxsMaking Inc. is trending due to discussions around its low float and potential for manipulation, with some traders pointing to its recent IPO and textile business. Community members are actively sharing their trading experiences, highlighting both successful exits and caution due to previous experiences with Chinese stocks. The stock's volatile movement and trading halts are also key points of discussion.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending due to a temporary halt in gene therapy trials after a patient experienced a liver injury, leading to a sharp decline in share price. The community is debating whether this is an overreaction and a buying opportunity, or a sign of deeper issues, while also assessing the potential impact on other gene editing stocks. Bullish investors are citing the company's assets, positive income, and potential for trial resumption, while bears are concerned about the severity of the adverse event.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X ($DGXX) is trending as investors discuss its potential in AI data centers, highlighted by Tier III certification and expansion plans. The community is watching for news of hyperscaler clients, data center launches, and strategic partnerships that could signal further growth. With Bitcoin mining experience and a pivot towards AI infrastructure, $DGXX is being compared to peers and speculated as an acquisition target.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with debates raging about whether the company will deliver a triple beat and if it can maintain its momentum. Community discussions also focus on potential rate cuts and the possibility of SoFi being added to the S&P 500, creating a mix of bullish sentiment and skepticism around valuation.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending as investors discuss the potential impact of the FDA label expansion and boxed warning on QTc prolongation, with some seeing it as a buying opportunity due to strong fundamentals and upcoming Q3 numbers. Community members highlight the company's $500M+ in cash, approved drugs, and inclusion in NCCN guidelines, while others compare SNDX to competitor $KURA, focusing on revenue and FDA approvals. Discussion also includes buyout potential and price target estimations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BTAI BTAI has publicly indicated intent to start TRANQUILITY In-Care soon after the At-Home results and has been evaluating CROs to operationalize the trial. It hasn’t publicly announced “first patient dosed” or posted a new Phase 3 In-Care start on http://ClinicalTrials.gov yet. 

Starting this trial will be a great step forward and positive results will be a game changer for Alzheimer’s and dementia patients. One report estimates the global Alzheimer’s agitation treatment market at ~ US$4.5 billion in 2024, and projects growth to around US$8.2 billion by 2033 (CAGR ~8 %) for that specific indication.

Canaccord Conference (Aug 12, 2025): “We have a protocol that [FDA] agreed on, ready to go… selecting a CRO… triggering the trial will be the next steps… basically ready to go very soon.”

HC Wainwright Conference (Sep 8, 2025): They had “agreement… for the Alzheimer’s program,” with CRO evaluations underway to initiate the trial.

Nick

Clinicaltrials

ClinicalTrials.gov

StockTwits for iOS

BioXcel Therapeutics Inc

 BTAI has publicly indicated intent to start TRANQUILITY In-Care soon after the At-Home results and has been evaluating CROs to operationalize the trial. It hasn’t publicly announced “first patient dosed” or posted a new Phase 3 In-Care start on 

 yet. 

Starting this trial will be a great step forward and positive results will be a game changer for Alzheimer’s and dementia patients. One report estimates the global Alzheimer’s agitation treatment market at ~ US$4.5 billion in 2024, and projects growth to around US$8.2 billion by 2033 (CAGR ~8 %) for that specific indication.

Canaccord Conference (Aug 12, 2025): “We have a protocol that [FDA] agreed on, ready to go… selecting a CRO… triggering the trial will be the next steps… basically ready to go very soon.”

HC Wainwright Conference (Sep 8, 2025): They had “agreement… for the Alzheimer’s program,” with CRO evaluations underway to initiate the trial.

BayAreaBiotech

@BayAreaBiotech okay well how bout the iglami or w/e the hell that has already passed phase 3 and they’re just sitting on their hands doing jack squat with no direct statements to shareholders about partnership or buyout or anything to bring revenue

 okay well how bout the iglami or w/e the hell that has already passed phase 3 and they’re just sitting on their hands doing jack squat with no direct statements to shareholders about partnership or buyout or anything to bring revenue

MakeM0ney_444

@MakeM0ney_444 true, but partnerships aren’t always a quick or simple process either. There’s a lot of negotiation, due diligence, and timing involved — especially when the company’s trying to maximize value.

BTAI probably wants to get the TRANQUILITY In-Care trial going first since a strong Alzheimer’s readout could put BXCL501 in an $8B+ market and give them way more leverage for any deal. Doing it too early could mean selling themselves short.

The best outcome will be to establish a partnership with a well known company with a strong commercial backbone. Ideally, partnership with sNDA acceptance and when the sNDA approval is obtained along with the Traquility results, the same company buys it at a premium price.

 true, but partnerships aren’t always a quick or simple process either. There’s a lot of negotiation, due diligence, and timing involved — especially when the company’s trying to maximize value.

BTAI probably wants to get the TRANQUILITY In-Care trial going first since a strong Alzheimer’s readout could put BXCL501 in an $8B+ market and give them way more leverage for any deal. Doing it too early could mean selling themselves short.

The best outcome will be to establish a partnership with a well known company with a strong commercial backbone. Ideally, partnership with sNDA acceptance and when the sNDA approval is obtained along with the Traquility results, the same company buys it at a premium price.

@BayAreaBiotech that’s all cool and all makes sense BUT THEYVE SAID NOTHING while their share price has been cut in (more) than half. Since the iglami. Don’t try to excuse their silence

 that’s all cool and all makes sense BUT THEYVE SAID NOTHING while their share price has been cut in (more) than half. Since the iglami. Don’t try to excuse their silence